Xeris Biopharma Holdings (XERS) Long-Term Investments (2020 - 2021)
Xeris Biopharma Holdings (XERS) posted Long-Term Investments of $33.5 million for Q3 2021, down 65.18% on a QoQ basis from $96.2 million in Q4 2020.
Xeris Biopharma Holdings (XERS) Long-Term Investments (2020 - 2021) Analysis & Trends
Xeris Biopharma Holdings' Long-Term Investments history runs 2 years deep, the most recent figure standing at $33.5 million for Q3 2021.
- Quarterly Long-Term Investments changed N/A year-over-year to $33.5 million in Q3 2021, while the trailing twelve-month figure through Sep 2021 was $33.5 million (changed N/A YoY) and the FY2020 annual result came in at $96.2 million, changed N/A from the prior year.
- Long-Term Investments was $33.5 million for Q3 2021 at Xeris Biopharma Holdings, down from $96.2 million in the prior quarter.
- Across five years, Long-Term Investments topped out at $96.2 million in Q4 2020 and bottomed at $33.5 million in Q3 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 56.09 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 1.32 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 702.35 Mn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 146.10 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Xeris Biopharma Holdings | 1.43 Bn | 1.32 Bn | 72.55 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 33.49 Mn |
| Dec 31, 2020 | 96.19 Mn |